10:32 , Apr 22, 2019 |  BC Extra  |  Company News

Lilly pays $35M up front to partner with Avidity on oligo conjugates

Lilly partnered with Avidity to develop antibody-oligonucleotide conjugates to treat immune diseases, with the biotech receiving $20 million up front and a $15 million investment. Avidity Biosciences LLC (La Jolla, Calif.) is eligible to receive...
22:17 , Mar 14, 2018 |  BC Innovations  |  Translation in Brief

Raising KRAS

For the first time, a joint research team from Wellspring Biosciences LLC and the Janssen Research & Development unit of Johnson & Johnson (NYSE:JNJ) showed a small molecule K-Ras (KRAS) inhibitor worked in animal models...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
19:12 , Dec 15, 2016 |  BC Innovations  |  Product R&D

p53 and Ras: Back from the dead

After decades of research and countless failed attempts at drug development, industry is reviving its interest in two of oncology’s most intractable targets, p53 and Ras. While no one denies there’s still a long road...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer K-Ras (KRAS) G12C In vitro studies suggest an allosteric, irreversible inhibitor of KRAS G12C could help treat cancer. A fragment-based screen yielded compounds that...
08:00 , Jan 9, 2014 |  BC Innovations  |  Targets & Mechanisms

Covalent hits on KRAS

University of California, San Francisco - and Harvard Medical School -led teams have independently synthesized the first covalent inhibitors of a common oncogenic form of KRAS . 1,2 Araxes Pharma LLC has licensed the UCSF...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Araxes Pharma, J&J deal

Araxes partnered with Johnson & Johnson's Janssen Biotech Inc. subsidiary to discover and develop therapeutics against an undisclosed target to treat cancer. Araxes, which is responsible for development through Phase I proof of concept, will...
02:08 , Feb 28, 2013 |  BC Extra  |  Top Story

Araxes debuts with Janssen cancer deal

Newco Araxes Pharma LLC (San Diego, Calif.) partnered with the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) to discover and develop therapeutics against an undisclosed target to treat cancer. Araxes, which is responsible...